These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27781556)

  • 1. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.
    Henter ID; de Sousa RT; Gold PW; Brunoni AR; Zarate CA; Machado-Vieira R
    Expert Rev Clin Pharmacol; 2017 Feb; 10(2):153-166. PubMed ID: 27781556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New targets for rapid antidepressant action.
    Machado-Vieira R; Henter ID; Zarate CA
    Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic Modulators in Depression.
    Henter ID; de Sousa RT; Zarate CA
    Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
    Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
    Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
    Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
    Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of glutamate in the pathophysiology of depression.
    Palucha A; Pilc A
    Drug News Perspect; 2005 May; 18(4):262-8. PubMed ID: 16034483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel glutamatergic drugs for the treatment of mood disorders.
    Lapidus KA; Soleimani L; Murrough JW
    Neuropsychiatr Dis Treat; 2013; 9():1101-12. PubMed ID: 23976856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
    Szakacs R; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
    Wang YT; Wang XL; Feng ST; Chen NH; Wang ZZ; Zhang Y
    Pharmacol Res; 2021 Sep; 171():105761. PubMed ID: 34242798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational NMDA receptor modulators for depression.
    Szewczyk B; Pałucha-Poniewiera A; Poleszak E; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2012 Jan; 21(1):91-102. PubMed ID: 22097925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular glutamate transporter 1 (VGLUT1)-mediated glutamate release and membrane GluA1 activation is involved in the rapid antidepressant-like effects of scopolamine in mice.
    Yu H; Li M; Zhou D; Lv D; Liao Q; Lou Z; Shen M; Wang Z; Li M; Xiao X; Zhang Y; Wang C
    Neuropharmacology; 2018 Mar; 131():209-222. PubMed ID: 29274366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Glutamatergic Treatments for Severe Mood Disorders.
    Park M; Niciu MJ; Zarate CA
    Curr Behav Neurosci Rep; 2015 Dec; 2(4):198-208. PubMed ID: 26824031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.